Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (361-370 of 471) with videos related to

Pageof 48
Sort By:
JAMA Cardiology|April 5, 2018
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialAlvin Chandra, Eldrin F Lewis, Brian L Claggett, et al.
European Journal of Heart Failure|June 1, 2005
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEileen O'Meara, Eldrin Lewis, Chris Granger, et al.
Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
Circulation. Heart Failure|December 15, 2012
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialDavid E Lanfear, Hani N Sabbah, Steven R Goldsmith, et al.
The Lancet. Diabetes & Endocrinology|March 24, 2017
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trialJelena P Seferovic, Brian Claggett, Sara B Seidelmann, et al.
Circulation|February 8, 2006
Renal function as a predictor of outcome in a broad spectrum of patients with heart failureHans L Hillege, Dorothea Nitsch, Marc A Pfeffer, et al.
American Heart Journal|July 15, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.
European Heart Journal|June 30, 2009
Effects of tolvaptan on dyspnoea relief from the EVEREST trialsPeter S Pang, Marvin A Konstam, Holly B Krasa, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
Cardiovascular Diabetology|June 18, 2022
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trialsMagnus O Wijkman, Brian Claggett, Muthiah Vaduganathan, et al.
Pageof 48

Showing results (361-370 of 471) with videos related to

Sort By:
Pageof 48
JAMA Cardiology|April 5, 2018
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialAlvin Chandra, Eldrin F Lewis, Brian L Claggett, et al.
European Journal of Heart Failure|June 1, 2005
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEileen O'Meara, Eldrin Lewis, Chris Granger, et al.
Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
Circulation. Heart Failure|December 15, 2012
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialDavid E Lanfear, Hani N Sabbah, Steven R Goldsmith, et al.
The Lancet. Diabetes & Endocrinology|March 24, 2017
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trialJelena P Seferovic, Brian Claggett, Sara B Seidelmann, et al.
Circulation|February 8, 2006
Renal function as a predictor of outcome in a broad spectrum of patients with heart failureHans L Hillege, Dorothea Nitsch, Marc A Pfeffer, et al.
American Heart Journal|July 15, 2006
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAnique Ducharme, Karl Swedberg, Marc A Pfeffer, et al.
European Heart Journal|June 30, 2009
Effects of tolvaptan on dyspnoea relief from the EVEREST trialsPeter S Pang, Marvin A Konstam, Holly B Krasa, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
Cardiovascular Diabetology|June 18, 2022
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trialsMagnus O Wijkman, Brian Claggett, Muthiah Vaduganathan, et al.
Pageof 48